quantisnow
FeedTopReportsPricing
⌘K
Live feed
07:00:00·120d
PRRelease
Repare Therapeutics Inc. logo

Repare Therapeutics Announces Acquisition of Polθ ATPase Inhibitor, RP-3467, by Gilead Sciences for Up To $30 Million in Total Consideration

RPTX· Repare Therapeutics Inc.
Health Care
Original source

Companies

  • RPTX
    Repare Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Jun 9UpdateStifel$16.00
  • Feb 3UpdateMorgan Stanley$15.00
  • Jan 6UpdateCapitalOne$28.00
  • Apr 12UpdateStifel$11.00
  • Mar 17UpdateGoldman$43.00
  • Sep 23UpdateStifel$48.00

Related

  • SEC81d
    SEC Form EFFECT filed by Repare Therapeutics Inc.
  • INSIDER83d
    SEC Form 4 filed by Large owner Bvf Partners L P/Il
  • SEC83d
    Amendment: SEC Form SCHEDULE 13D/A filed by Repare Therapeutics Inc.
  • INSIDER85d
    Director Rhoads Ann D returned 4,000 shares to the company, closing all direct ownership in the company (SEC Form 4)
  • INSIDER85d
    Director Schafer Carol returned 8,000 shares to the company, closing all direct ownership in the company (SEC Form 4)
  • INSIDER85d
    EVP, CHIEF FINANCIAL OFFICER Forte Steve returned 56,786 shares to the company, closing all direct ownership in the company (SEC Form 4)
  • INSIDER85d
    Director Civik Thomas returned 7,500 shares to the company, closing all direct ownership in the company (SEC Form 4)
  • INSIDER85d
    SVP, Finance and CAO Alves Sandra Isabelle Barros returned 31,622 shares to the company, closing all direct ownership in the company (SEC Form 4)
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022